Impact of Tacrolimus, Sirolimus, Age, and Body Mass Index on the Occurrence of Skin Cancer and Islet Dysfunction After Transplantation.

Cell Transplant · 2025 · PMC11713960 · PMID 39780302

Europe PMC DOI

hedged sentence

0.7900

closest p · 15.8× alpha

0.7900

boldest claim

The sentences

did not reach statistical significanceP = 0.79not close (p > 0.1)

Tacrolimus and sirolimus trough level differences between skin cancer versus non-skin cancer individuals did not reach statistical significance (mean ± SD 4.81 ± 0.66 ng/ml versus 4.65 ± 0.72 ng/ml, P = 0.79 for tacrolimus, respectively, and 9.4 ± 2.2 ng/ml versus 10.8 ± 4.1 ng/ml, P = 0.73 for sirolimus, respectively, Table 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.